1. Home
  2. PROK vs NERV Comparison

PROK vs NERV Comparison

Compare PROK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.65

Market Cap

359.1M

Sector

Health Care

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.51

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROK
NERV
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
359.1M
301.6M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
PROK
NERV
Price
$1.65
$4.51
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$7.40
$10.50
AVG Volume (30 Days)
988.6K
120.8K
Earning Date
05-08-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$893,000.00
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1075.00
N/A
52 Week Low
$0.54
$1.57
52 Week High
$7.13
$12.46

Technical Indicators

Market Signals
Indicator
PROK
NERV
Relative Strength Index (RSI) 41.23 36.18
Support Level $1.55 $4.30
Resistance Level $2.59 $4.59
Average True Range (ATR) 0.12 0.37
MACD -0.01 0.01
Stochastic Oscillator 11.43 13.70

Price Performance

Historical Comparison
PROK
NERV

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: